Use of Biperiden for the Prevention of Post-traumatic Epilepsy

Overview

There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.

Full Title of Study: “Use of Biperiden as a Disease Modifying Agent After Traumatic Brain Injury: a Placebo Controlled, Randomized, Double Blind Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: December 2, 2022

Detailed Description

Treatment with biperiden should be initiated in the first 12 hours after trauma as means to avoid the epileptogenic process. The treatment will be repeated every 6 hours for 10 consecutive days. The efficacy of biperiden as an antiepileptogenic drug will be established by analyzing the development of PTE between the biperiden and placebo groups. Several patients' aspects (clinical, electroencephalography, brain imaging, genetic and behavioral data) will be monitored for two year follow-up to unravel the mechanisms by which biperiden exerts its actions on epileptogenesis. The investigators are already at the early stages of patient's recruitment using the available resources.

Interventions

  • Drug: Biperiden Lactate
    • 5mg IV(in the vein)every 6 hours for 10 days
  • Drug: Placebo
    • 5mg IV(in the vein)every 6 hours for 10 days

Arms, Groups and Cohorts

  • Experimental: Biperiden Lactate
    • 5mg IV(in the vein)every 6 hours for 10 days
  • Placebo Comparator: Placebo
    • 5mg IV(in the vein)every 6 hours for 10 days

Clinical Trial Outcome Measures

Primary Measures

  • Clinical Outcome: Indidence of post-traumatic epilepsy
    • Time Frame: 24 months after TBI
    • The incidence of seizures will be evaluated starting immediately after TBI and continuously during the hospitalization period and after hospital discharge during the two year follow up period. Patients and their relatives will be asked to maintain a diary of seizures, and thus record all seizures with detailed descriptions of each event. The recordings will be evaluated in each patient visit. Seizures incidence will be compared between placebo and biperiden-treated patients.

Secondary Measures

  • Frequency of seizures
    • Time Frame: 24 months after TBI
    • The frequency of seizures will be counted starting immediately after TBI and continuously during the hospitalization period and after hospital discharge during the two year follow up period. Frequency of seizure will be compared between placebo and biperiden-treated patients.
  • Mortality and adverse effects
    • Time Frame: 24 months after TBI
    • The incidence of death and adverse effects will be counted starting immediately after TBI and continuously during the hospitalization period and after hospital discharge during the two year follow up period. Incidence of death and adverse effects will be compared between placebo and biperiden-treated patients.

Participating in This Clinical Trial

Inclusion Criteria

  • between 18 and 75 year of age – patients with a diagnosis of acute TBI admitted to an emergency unit within 12 hours of the accident, regardless of the accident – brain CT scan with signs of acute intraparenchymatous contusion – signed informed consent (possibly by a relative) Exclusion Criteria:

  • malignant neoplasia and other severe comorbidities – neurodegenerative disorders – previous cerebrovascular accident – record of convulsive seizures or use of anti-epileptic medication – pregnancy – concomitant use of the other anticholinergic medications – presence of any factor that may contraindicate the use of biperiden – participation in other clinical trial – alcohol intoxication will not lead to exclusion of the subject.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Federal University of São Paulo
  • Collaborator
    • University of Sao Paulo
  • Provider of Information About this Clinical Study
    • Principal Investigator: Luiz Eugenio Mello, Full Professor – Federal University of São Paulo
  • Overall Official(s)
    • Luiz Mello, Principal Investigator, Federal University of São Paulo

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.